

Supporting information

Evaluation of Age-Related Changes in Teneligliptin Pharmacokinetics in Japanese and Caucasian Subjects Using a Physiologically Based Pharmacokinetic Model

Hiroaki Iijima, Hidetoshi Shimizu, Kazumi Mori-Anai, Atsuhiro Kawaguchi, Yoji Mochida, Toshimasa Yamauchi, Takashi Kadowaki


Contents

Supplementary Table 1. Summary of patient characteristics and pharmacokinetic parameters (Another PDF file)

Supplementary Fig. 1. Simulated PK parameters after a single dose of 20 mg teneligliptin. (This file)

Supplementary Fig. 2. Simulated PK parameters after multiple doses of 20 mg teneligliptin for 7 days. (This file)


Supplementary Table 2. Ratio of PK parameters for each age-group versus the youngest age-group (≥ 20 to < 25 years) for multiple doses of 20 mg teneligliptin in virtual Japanese and Caucasian populations. (This file)



Supplementary Fig. 1. Simulated PK parameters after a single dose of 20 mg teneligliptin

Age versus $t_{1/2}$ (a) and t_{max} (b). Values are shown as the mean $\pm$ standard deviation for age and both PK parameters in Japanese (20–70 years; red) and Caucasian (20–98 years; blue). Age was divided into 5-year categories (4 years for ≥ 90 years old) populations.

PK, pharmacokinetic; t_{max} , time to the maximum concentration; $t_{1/2}$, elimination half-life



Supplementary Fig. 2. Simulated PK parameters after multiple doses of 20 mg teneligliptin in virtual Japanese and Caucasian populations

Age versus AUC_{0-24h} (a) and C_{max} (b). Values are shown as the mean $\pm$ standard deviation for age and both PK parameters in Japanese (20–70 years; red) and Caucasian (20–98 years; blue). Age was divided into 5-year categories (4 years for ≥ 90 years old) populations. AUC_{0-24h} , area under the plasma concentration–time curve from 0 to 24 h; C_{max} , maximum concentration; PK, pharmacokinetic

Supplementary Table 2. Ratio of PK parameters for each age-group versus the youngest age-group (≥ 20 to < 25 years) for multiple doses of 20 mg teneligliptin in virtual Japanese and Caucasian populations

Age-group (years)	Multiple doses			
	Japanese		Caucasian	
	AUC _{0–24h}	C _{max}	AUC _{0–24h}	C _{max}
≥ 20 to < 25 (reference)	1.00	1.00	1.00	1.00
≥ 25 to < 30	1.01	1.01	0.94	1.00
≥ 30 to < 35	1.03	1.03	0.98	1.03
≥ 35 to < 40	1.00	0.95	1.02	0.98
≥ 40 to < 45	1.06	1.00	1.07	1.00
≥ 45 to < 50	1.08	1.03	1.07	1.05
≥ 50 to < 55	1.14	1.05	1.17	1.12
≥ 55 to < 60	1.16	1.01	1.25	1.08
≥ 60 to < 65	1.29	1.10	1.34	1.12
≥ 65 to < 70	1.33	1.14	1.27	1.07
≥ 70 to < 75	N.A.	N.A.	1.70	1.35
≥ 75 to < 80	N.A.	N.A.	1.71	1.23
≥ 80 to < 85	N.A.	N.A.	1.93	1.41
≥ 85 to < 90	N.A.	N.A.	1.94	1.40
≥ 90 to < 94	N.A.	N.A.	2.08	1.49
≥ 94 to ≤ 98	N.A.	N.A.	2.00	1.44

AUC_{0–24h}, area under the curve from 0 to 24 h; C_{max}, maximum plasma concentration;

N.A., not available